Efficacy and tolerability of combined dipyrone, isometheptene and caffeine in the treatment of mild-to-moderate primary headache episodes

References

• Bigal ME, Rapoport AM, Hargreaves R. Advances in the pharmacologic treatment of tension-type headache. Curr. Pain Headache Rep.12(6), 442–446 (2008).
   PubMed Web of Science ®Google Scholar
• Carvalho DS, Rabello GD, Figueiró JAB et al. [Dipyrone plus caffeine versus dipyrone alone to acute treatment of mild to moderate primary headache attacks: a double blind, randomized, compared clinical study]. Rev. Bras. Med.64(6), 273–278 (2007).
   Google Scholar
• Suarez-Kurtz G, Ribeiro FM, Estrela RCE et al. Limited-sampling strategy models for estimating the pharmacokinetic parameters of 4-methylaminoantipyrine, an active metabolite of dipyrone. Braz. J. Med. Biol. Res.34, 1475–1485 (2001).
   PubMedGoogle Scholar
• Fendrich Z. [Metamizol – a new effective analgesic with a long history. Overview of its pharmacology and clinical use]. Cas. Lek. Cesk.139, 440–444 (2000).
   PubMedGoogle Scholar
• Martinez-Martín P, Rafaelli E, Titus F et al. Efficacy and safety of metamizol vs. acetylsalicylic acid in patients with moderate episodic tension-type headache: a randomized, double-blind, placebo- and active-controlled, multicentre study. Cephalalgia21, 604–610 (2001).
   PubMed Web of Science ®Google Scholar
• Remington’s Pharmaceutical Sciences. 17th Edition. Osol A, Chase GD, Gennaro AR et al. (Eds). Mack, Easton, PA, USA, 891–892 (1985).
   Google Scholar
• Willems EW, Valdivia LF, Saxena PR, Villalon CM. Pharmacological profile of the mechanisms involved in the external carotid vascular effects of the antimigraine agent isometheptene in anaesthetized dogs. Naunyn Schmiedebergs Arch. Pharmacol.364, 27–32 (2001).
   PubMedGoogle Scholar
• Engelhardt G, Mauz AB, Pairet M. Role of caffeine in combined analgesic drugs from the point of view of experimental pharmacology. Arzneimittelforschung47, 917–927 (1997).
   PubMedGoogle Scholar
• Nehlig A, Daval JL, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res. Brain Res. Rev.17, 139–170 (1992).
   PubMed Web of Science ®Google Scholar
• Silva Neto RP, Soares AA. [Role of caffeine in headaches: aggravating or attenuating factor]. Migrâneas Cefaléias9, 72–77 (2006).
   Google Scholar
• Migliardi JR, Armellino JJ, Gillings DB, Beaver WT. Caffeine as an analgesic adjuvant in tension headache. Clin. Pharmacol. Ther.56, 576–585 (1994).
   PubMed Web of Science ®Google Scholar
• Zhang WY. A benefit–risk assessment of caffeine as an analgesic adjuvant. Drug Saf.24, 1127–1142 (2001).
   PubMed Web of Science ®Google Scholar
• Martindale W. Martindale – The Complete Drug Reference. 32nd Edition. Parfit K (Ed.). Pharmaceutical Press, Tauton, MA, USA, 72–75 (1999).
   Google Scholar
• Flower RJ, Moncada S, Vane JR. Analgesic-antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout. In: The Pharmacologic Basis of Therapeutics. 7th Edition. Gilman AG, Goodman LS, Gilman A (Eds). Pergamon Press Inc, Elmsford, NY, USA, 692–695 (1985).
   Google Scholar
• Bjorkman R, Hallman KM, Hedner J, Hedner T, Henning M. Acetaminophen blocks spinal hyperalgesia induced by NMDA and substance P. Pain57, 259–264 (1994).
   PubMed Web of Science ®Google Scholar
• Goldberg H, Nunes CP, Fonseca AS et al. A double-blind, randomized, crossover study of the safety and efficacy of a combination of carisoprodol, paracetamol, caffeine, and B-vitamins in the treatment of spastic muscle contractures. Rev. Bras. Med.64, 265–272 (2007).
   Google Scholar
• International Headache Society Committee on Clinical Trials: guidelines for trials of drug treatments in tension-type headache. Cephalalgia15, 165–179 (1995).
   PubMed Web of Science ®Google Scholar
• Lipsitz SH, Kim K, Zhao L. Analysis of repeated categorical data using generalized estimating equations. Stat. Med.13, 1149–1163 (1994).
   PubMed Web of Science ®Google Scholar
• Molenberghs G, Verbeke G. Models for Discrete Longitudinal Data. Springer-Verlag, New York, NY, USA (2006).
   Google Scholar
• Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System, 2nd Edition. SAS Institute Inc., Cary, NC, USA (2000).
   Google Scholar
• Frey GH. The role of placebo response in clinical headache evaluation. Headache1, 31–138 (1961).
   PubMedGoogle Scholar
• Weisman L. Experimental design in headache treatment. Headache10, 165–170 (1971).
   Google Scholar
• Bigal ME, Bigal JOM, Bordini CA, Speciali JG. [Evaluation of placebo use in migraine without aura, migraine with aura and episodic tension-type headache acute attacks]. Arq. Neuropsiquiatr.59, 552–558 (2001).
   PubMedGoogle Scholar
• Tfelt-Hansen P. How to define the best efficacy parameters for migraine. Cephalalgia17(Suppl. 4), 6–9 (1997).
   PubMedGoogle Scholar
• Diener HC, Dowson AJ, Ferrari M, Nappi G, Tfelt-Hansen P. Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials. Cephalalgia19, 699–700 (1999).
   PubMed Web of Science ®Google Scholar
• Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N. Engl. J. Med.344, 1594–1602 (2001).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia22, 633–658 (2002).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Prioritizing acute pharmacotherapy of migraines. In: The Headaches. Olesen, J, Gadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (Eds). Lippincott, Philadelphia, PA, USA, 515–517 (2006).
   Google Scholar
• Lipton RB, Bigal ME. Headache as a real disease. Headache48, 707–710 (2008).
   PubMedGoogle Scholar
• Arrais PS, Coelho HL, Batista Mdo C, Carvalho ML, Righi RE, Arnau JM. [Profile of self-medication in Brazil]. Rev Saude Publica31, 71–77 (1997).
   PubMedGoogle Scholar
• Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA290, 2443–2454 (2003).
   PubMed Web of Science ®Google Scholar
• Bigal ME, Bordini CA, Speciali JG. Intravenous dipyrone for the acute treatment of episodic tension-type headache: a randomized, placebo-controlled, double-blind study. Braz. J. Med. Biol. Res.35, 1139–1145 (2002).
   PubMedGoogle Scholar
• Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo controlled study. Headache42, 862–871 (2002).
   PubMedGoogle Scholar
• Bigal ME, Bordini CA, Speciali JG. [Efficacy of three drugs in the treatment of migrainous aura: a randomized placebo-controlled study.] Arq. Neuropsiquiatr.60, 406–409 (2002).
   PubMedGoogle Scholar
• Wong A. A reappraisal of antipyretic and analgesisc drugs. WHO Pharmaceuticals Newsletter1, 15–16 (2002).
   Google Scholar
• Hamerschlak N, Maluf E, Biasi Cavalcanti A et al. Incidence and risk factors for agranulocytosis in Latin American countries – the Latin Study: a multicenter study. Eur. J. Clin. Pharmacol.64(9), 921–929 (2008).
   PubMedGoogle Scholar
• Maluf E, Hamerschlak N, Cavalcanti AB et al. Incidence and risk factors of aplastic anemia in Latin American countries: the LATIN case–control study. Haematologica94(9), 1220–1226 (2009).
   PubMed Web of Science ®Google Scholar
• Ramacciotti AS, Soares B, Atallah ÁN. Dipyrone for acute primary headaches. Cochrane Database Syst. Rev.2, CD004842 (2007).
   Google Scholar